Genedata expands in the U.K.

Wednesday, February 22, 2017

Genedata, a provider of advanced software solutions for biopharmaceutical and biotech research and development (R&D), announced the establishment of Genedata Limited as a new subsidiary in the U.K. The company is headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the U.K. subsidiary reinforces Genedata’s commitment to collaborate closely with its rapidly growing client base in the U.K., one of the most exciting biotech hubs in the world, in particular in the high-potential field of precision medicine. 

[Read More]

Luxcel Biosciences, Axiogenesis, BMG LABTECH to develop cell metabolism analysis platform

Thursday, February 16, 2017

Three European technology SMEs, together with two research institutions, Oxford University and Imperial College London, have been awarded €2.5 million funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development. 

[Read More]

Milner Therapeutics Institute, Pfizer partner

Friday, January 20, 2017

The Milner Therapeutics Institute has announced Pfizer as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr. Ron Newbold, vice president, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.

[Read More]

AbbVie, Genomics Medicine Ireland and WuXi NextCODE partner

Monday, January 9, 2017

AbbVie, a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland (GMI), and WuXi NextCODE, a global contract genomics organization, has announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide. Financial terms were not disclosed.

[Read More]

EMA to offer advice for new biosimilars

Tuesday, December 20, 2016

The EMA will launch a pilot project in February 2017 to test the added value and feasibility of tailored scientific advice for the development path of biosimilar medicines. Through this new initiative, EMA aims to provide developers of biosimilars with advice on the studies/tests they should be conducting, on the basis of the quality, analytical and functional data they have already available for the medicine.

[Read More]